Related Experiment Video
Updated: Aug 15, 2025
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
Pharmacotherapy Evolution in Alzheimer's Disease: Current Framework and Relevant Directions
Denisa Claudia Miculas1, Paul Andrei Negru1, Simona Gabriela Bungau1,2
1Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
Cells
|January 8, 2023
Summary
Alzheimer's disease (AD) treatments offer limited benefits. New research focuses on curing underlying causes and slowing progression through comprehensive clinical studies and drug analysis.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Alzheimer's disease (AD) is the most common dementia in the elderly.
- Current AD drugs provide symptomatic relief but no cure.
- There is a critical need for disease-modifying treatments.
Purpose of the Study:
- To review current Alzheimer's disease treatment strategies.
- To summarize clinical features and pharmacological properties of existing medications.
- To discuss molecular docking analyses of current AD drugs.
Main Methods:
- Literature review of Alzheimer's disease treatments.
- Analysis of clinical trial phases (I, II, III).
- Examination of pharmacological properties and molecular docking.
Main Results:
- Existing treatments offer limited efficacy for most patients.
- Clinical studies are exploring cognitive improvement and disease biology.
- Molecular docking provides insights into drug mechanisms.
Conclusions:
- Novel therapeutic strategies are essential for Alzheimer's disease.
- Comprehensive studies targeting AD's core biology are imperative.
- Further research is needed to develop curative treatments.
Keywords:
Alzheimer’s diseasecholinesterase inhibitorscognitive improvementglutamate antagonistssymptom reductionMore Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
238
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
238
01:26Alzheimer's Disease: Overview
600
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
600
01:28Drug Therapy
83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
83
01:26Psychosis: Goals of Pharmacotherapy
185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185
01:24Parkinson's Disease: Treatment
333
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
333
01:26Drug Administration and Therapy Phases: Overview
618
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
618